Skip to main content
Cinclus Pharma Holding AB logo

Cinclus Pharma Holding AB — Investor Relations & Filings

Ticker · CINPHA ISIN · SE0020388577 LEI · 549300TJBPSNZ3DO6B42 ST Manufacturing
Open in API
Filings indexed 68 across all filing types
Latest filing 2024-07-11 Regulatory Filings
Country SE Sweden
Listing ST CINPHA

About Cinclus Pharma Holding AB

https://cincluspharma.com/

Cinclus Pharma Holding AB is a clinical-stage pharmaceutical company focused on developing treatments for gastric acid-related diseases. The company's lead drug candidate is linaprazan glurate, a Potassium-Competitive Acid Blocker (PCAB) in late-stage clinical development. This therapeutic is being developed to treat gastroesophageal reflux disease (GERD), particularly severe erosive GERD, and for the eradication of Helicobacter pylori infections. Linaprazan glurate represents a next-generation approach, aiming to provide superior clinical efficacy and a more beneficial pharmacokinetic profile compared to traditional Proton Pump Inhibitors (PPIs). The goal is to address the unmet medical needs of patients who do not achieve sufficient disease control with current therapies.

Recent filings

Filing Released Lang Actions
Meddelande om stabiliseringsåtgärder
Regulatory Filings Classification · 95% confidence The document is a press release from Cinclus Pharma regarding 'stabilization measures' taken by Carnegie Investment Bank following an IPO. It details specific transaction data (dates, volumes, prices) related to share stabilization on Nasdaq Stockholm. While it contains financial data, it is a regulatory announcement required under the EU Market Abuse Regulation (MAR) rather than a formal financial report or a report publication announcement. Given the specific nature of stabilization disclosures, it falls under the general regulatory filing category.
2024-07-11 Swedish
Stabilization notice
Share Issue/Capital Change Classification · 100% confidence The document is a 'Stabilization Notice' issued by Carnegie Investment Bank regarding Cinclus Pharma Holding AB. It details specific stabilization transactions (share buybacks/support) conducted on Nasdaq Stockholm following an IPO. While it contains transaction data, it is a regulatory disclosure required under the EU Market Abuse Regulation. Since it is a specific regulatory announcement regarding market stabilization activities rather than a general corporate filing or a report publication announcement, it fits best under the 'Regulatory Filings' category as a fallback for specific market abuse disclosures.
2024-07-11 English
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 100% confidence The document is a 'flaggningsmeddelande' (flagging notification) filed with the Swedish Financial Supervisory Authority (Finansinspektionen). It details a change in shareholding where Futur Pension Holding AB has crossed the 5% threshold in Cinclus Pharma Holding AB. This is a classic major shareholding notification, which corresponds to the 'Major Shareholding Notification' category.
2024-07-02 Swedish
Stabilization notice
Regulatory Filings Classification · 95% confidence The document is a press release from Cinclus Pharma regarding a 'Stabilization Notice' following an initial public offering. It details stabilization measures taken by the stabilization manager (Carnegie Investment Bank) on Nasdaq Stockholm, including a table of specific transaction dates, volumes, and prices. While it contains specific data, it is a regulatory announcement required by the EU Market Abuse Regulation. It does not fit into categories like '10-K' or 'IR' (which are periodic financial reports) or 'POS' (which refers to a company buying back its own shares, whereas this is stabilization by an underwriter). Given the nature of the disclosure regarding market stabilization activities, 'RNS' (Regulatory Filings) is the most appropriate classification for this type of regulatory announcement.
2024-07-01 English
Meddelande om stabiliseringsåtgärder
Share Issue/Capital Change Classification · 100% confidence The document is a press release titled 'Meddelande om stabiliseringsåtgärder' (Announcement of stabilization measures) issued by Carnegie Investment Bank regarding Cinclus Pharma Holding AB. It details stabilization transactions conducted on Nasdaq Stockholm following an IPO, including specific dates, volumes, and price ranges. While it contains transaction data, it is a formal regulatory announcement required under EU Market Abuse Regulation (MAR). It does not fit into 'Transaction in Own Shares' (which usually refers to buybacks by the issuer itself) or 'Regulatory Filings' (as it is a specific type of market announcement). Given the nature of the document as a formal announcement of stabilization activities, it is best classified as a Regulatory Filing (RNS) as it serves as a mandatory disclosure of market activity.
2024-07-01 Swedish
Number of shares and votes in Cinclus Pharma
Share Issue/Capital Change Classification · 100% confidence The document is a press release announcing a change in the total number of shares and votes in Cinclus Pharma following a recent share issue. This falls under the category of capital changes and share issuance announcements. According to the provided definitions, 'SHA' (Share Issue/Capital Change) is the most accurate classification for announcements regarding new share issues and changes in share capital.
2024-06-28 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.